Back to Screener

Healthcare

Lexeo Therapeutics, Inc. Common Stock(LXEO)

Live Price

Offline

$4.70

-3.89% today

1Y Change

+16.92%

Window

Jun 30, 2025 โ†’ Jun 25, 2026

Market Cap
$430.00M
Revenue Growth
0.0%
EPS Growth
+39.8%
Dividend Yield
0.0%

Coverage: 248 bars ยท Jun 30, 2025 โ†’ Jun 25, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Lexeo Therapeutics, Inc. Common Stock (LXEO) is a Healthcare stock with a market cap of $430.00M and listed on NASDAQ. The stock last traded around $4.70 and up 16.9% across the available one-year price window (Jun 30, 2025 โ†’ Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +39.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +39.8%, free cash flow -21.2% with operating margin 0.0% and ROIC -42.9%. Stock Foundry combines LXEO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

LXEO vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

LXEO trails SPY

LXEO is 1.93 pts behind over the shared 1Y window.

LXEO had 52.01 pts deeper max drawdown than SPY.

LXEO beat SPY in 1 of 2 calendar years shown and trailed in 1.

LXEO

+16.92%

Normalized return

SPY

+18.85%

S&P 500

Excess Return

-1.93 pts

Relative to SPY

LXEO Max Drawdown

-61.15%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

LXEOSPY

Calendar-Year Returns

Uses the longest available daily history for LXEO and SPY.

YearLXEOSPYExcessLeader
2026-51.09%+6.71%-57.80 ptsSPY
2025+142.29%+11.19%+131.09 ptsLXEO

Unable to load analyst forecasts.

Timed out loading forecasts for LXEO

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.